Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19
Status:
Not yet recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A randomized double blind control trial will be done. Total 188 Covid-19 patients will be
enrolled in this trial who are RT-PCR confirmed case of mild cases. Before enrollment, base
line investigations will be done and as per eligibility criteria 188 (one hundred eighty
eight) patients of mild symptoms will be selected by random sampling. Ninety four diagnosed
patients (Group-A) of Covid-19 will be in the experimental group and 94 Covid-19 diagnosed
patients (Group-B) will be in the control group.
Group -A will be given combination treatment of Tab Ivermectin and Cap Doxycycline along with
standard therapy and Group -B will be treated by standard therapy with placebo.
Follow up will be done every day in both group with all the parameters as stated above and
will be documented.
On 5th day of treatment, if fever subsides final outcome will be measured by result of RT-PCR
test preferably from one designated lab with sample of nasal swab for all. Subject to RT-PCR
test negative result again on 6th day another RT-PCR test will be done at 24 hours apart. But
if RT-PCR test result remain positive on 5th day, again on 10th day same test is to be done
and also on 11th day subject to test result as negative on 10th day.
Death of the patients will be documented as well. Regarding safety issues of the drugs we
shall monitor for any SAE and would report to the DSMB for proper management guideline